Our Story


We have chosen to focus on developing new drugs for hard-to-treat cancers. We believe we can make a difference in improving therapeutic options and quality-of-life for patients fighting such cancers.

Our unique DRP® companion diagnostics match the right patients to each of our drugs. Our mission is to help patients with hard-to-treat cancers by embracing precision oncology. The three drug candidates in our pipeline focus on breast, ovarian, prostate, pancreatic endometrial and primary and metastatic brain tumors.

The benefit of our approach is that we de-risk and accelerate the clinical development of drugs in our pipeline and we improve the efficacy outcomes. This strategy should enable us to more rapidly bring new drugs to market for use in precision oncology.